Effects of Different Doses of Cyclophosphamide on the Peripheral Blood Biochemical Indicators of Fujian Yellow Rabbit

doi:10.11924/j.issn.1000-6850.casb2021-1197

Abstract

Abstract:

The study aims to investigate the effects of different doses of cyclophosphamide on the peripheral blood biochemical indicators of Fujian yellow rabbit, and provide experimental reference for establishing the immunosuppressive animal model of Fujian yellow rabbit. Eighteen Fujian yellow rabbits (4 months old) were randomly divided into control group and model groups. The model groups were intraperitoneally injected with 20, 40, 60, 80 and 100 mg/kg cyclophosphamide for 7 consecutive days, respectively. Peripheral blood was collected on the 8th day. The results showed that different doses of cyclophosphamide caused significant changes in electrolytes (K, Na, Cl, Ca, Mg, P, HCO₃^-, AG and POP), muscle enzymes(LDH, CK and CKMB), blood glucose(GLU), blood lipids(CHOL, TG, HDLC, LDLC, A1APOA1 and BAPOB), liver function(TBIL, DBIL, IBIL, TP, ALB, GLB, ALT, AST, GGT, AST/ALT and ALP), renal function(BUN, CR and UA) and other indicators in peripheral blood compared with the control group, and a dose-dependent relationship was observed. Different doses of cyclophosphamide had no significant effects on the level of BAPOB/A1APOA1(B/A1) and ALB/GLB(A/G). With the increase of the dose of cyclophosphamide, the liver and renal functions of Fujian yellow rabbit were seriously affected, indicating a decreasing trend in the physiological and immune functions.

Key words: Fujian yellow rabbit, cyclophosphamide, liver, kidney, biochemical indicators, immune function

WANG Yan, YU Chunying, ZHOU Jianhua, YANG Yanyan, XIE Jindong, ZHONG Qiuming, WANG Xunli. Effects of Different Doses of Cyclophosphamide on the Peripheral Blood Biochemical Indicators of Fujian Yellow Rabbit[J]. Chinese Agricultural Science Bulletin, 2023, 39(2): 88-92.

Figures/Tables 6

References 20

[1]	MOIGNET A, HASANALI Z, ZAMBELLO R, et al. Cyclophosphamide as a first-line therapy in LGL leukemia[J]. Leukemia, 2013, 28:1134-1136. doi: 10.1038/leu.2013.359 URL
[2]	GEISLER C H. Cyclophosphamide for CLL: to be or not CYP2B activated?[J]. Blood, 2013, 122:4156-4157. doi: 10.1182/blood-2013-10-534115 pmid: 24357708
[3]	SCURR M J, PEMBROKE T, BLOOM A, et al. Low dose cyclophosphamide induces antitumor T cell responses which associate with survival in metastatic colorectal cancer[J]. Clinical cancer research, 2017, 23(22):6771-6780. doi: 10.1158/1078-0432.CCR-17-0895 URL
[4]	郭智, 童春, 刘晓东, 等. 单倍型异基因造血千细胞移植后大剂量环磷酰胺诱导免疫耐受治疗儿童重型再生障碍性贫血[J]. 中国组织工程研究, 2016, 20(32):4818-4824.
[5]	VOGT U, SCHLOTTER C M, BOSSE U, et al. Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therapy study applying docetaxel/epirubicin/cyclophosphamide(TEC)[J]. Eur J cancer suppl, 2006, 4(6):2-13.
[6]	FLEMING RA. Overview of cyelophoshamide and ifosfamide pharmacology[J]. Pharmacotherapy, 1997, 17(suppl.5):146.
[7]	刘俊业, 李乐乐, 江素鑫, 等. 环磷酰胺的临床应用及其毒性防治[J]. 吉林医药学院学报, 2019, 40(6):449-451.
[8]	谢喜平, 陈岩锋, 孙世坤, 等. 福建黄兔报种及创新利用的研究与实践[J]. 中国养兔杂志, 2006(6):3-5.
[9]	俞春英, 谢金东, 李秀红, 等. 福建黄兔与新西兰白兔血液生理生化指标的比较研究[J]. 福建中医学院学报, 2010, 20(2):36-39.
[10]	AHLMANN M, HEMPEL G. The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy[J]. Cancer chemother pharmacol, 2016, 78(4):661-671. doi: 10.1007/s00280-016-3152-1 URL
[11]	康慧琳, 樊卫平, 雷波, 等. 不同剂量环磷酰胺对小鼠免疫功能的影响[J]. 免疫学杂志, 2018, 34(4):308-312
[12]	GUNES S, SAHINTURK V, USLU S, et al. Protective effects of selenium on cyclophosphamide induced oxidative stress and kidney injury[J]. Biological trace element research, 2018, 185(1):116-123. doi: 10.1007/s12011-017-1231-8 URL
[13]	袁洪超, 苏晶, 高潇, 等. 国内应用免疫抑制剂制作免疫抑制动物模型的研究进展[J]. 国际免疫学杂志, 2014, 37(2):137-140.
[14]	NARLA S T, BUSHNELL D S, SCHAEFER C M, et al. Keratinocyte growth factor reduces injury and leads to early recovery from cyclophosphamidc bladder injury[J]. The American journal of pathology, 2020, 190(1):108-124. doi: 10.1016/j.ajpath.2019.09.015 URL
[15]	李雷勇, 田岳凤, 翟春涛. 环磷酰胺对兔免疫功能抑制作用的效应分析[J]. 医学动物防制, 2020, 36(2):152-156.
[16]	李小全, 王跃玲, 李伟华, 等. 血脂及血清胆碱酯酶、转氨酶水平检测在脂肪肝患者病情评估中的应用价值[J]. 医药论坛杂志, 2019, 40(3):136-137.
[17]	韦凤华. 环磷酰胺临床应用研究进展[J]. 中国药事, 2013, 27(3):324-326
[18]	伍维高, 钟金凤. 环磷酰胺构建动物免疫抑制模型的研究进展[J]. 中国兽医杂志, 2019, 55(2):87-89.
[19]	王燕, 周建华, 俞春英, 等. 环磷酰胺对福建黄兔肝肾损伤的试验研究[J]. 福建畜牧兽医, 2022, 44(2):8-11.
[20]	谢喜平, 孙世坤, 陈冬金, 等. 福建本地兔资源开发利用现状及展望[J]. 中国养兔, 2012(1):24-27.

项目	0	20/(mg/kg)	40/(mg/kg)	60/(mg/kg)	80/(mg/kg)	100/(mg/kg)
钾(K)	4.5±0.2	4.9±0.1	5.0±0.3	5.4±0.2	6.1±0.3*	6.8±0.2**
钠(Na)	139.1±3.3	135.9±2.5	133.1±2.3	120.0±3.1	107.9±4.2*	98.7±3.5**
氯(Cl)	101.1±1.2	97.9±1.4	95.6±1.2	90.0±1.5	77.2±1.3*	69.7±1.4**
钙(Ca)	2.4±0.1	2.3±0.2	2.0±0.4	1.8±0.2	1.2±0.1*	1.0±0.3**
镁(Mg)	1.0±0.2	0.9±0.1	1.4±0.3	2.0±0.1	2.9±0.2*	3.7±0.1**
磷(P)	1.2±0.1	1.3±0.3	1.8±0.1	2.2±0.1	3.1±0.2*	4.6±0.1**
碳酸氢根	24.2±0.7	22.5±0.4	20.9±0.8	18.8±0.6	14.3±0.8*	10.4±0.5**
阴离子间隙	14.2±0.5	12.4±0.4	11.7±0.5	10.0±0.6	7.0±0.5*	5.8±0.6**
渗透压(mOSM/L)	300.1±4.3	275.9±5.5	253.1±4.3	230.0±5.1	201.9±4.2*	180.7±4.5**

项目	0	20/(mg/kg)	40/(mg/kg)	60/(mg/kg)	80/(mg/kg)	100/(mg/kg)
钾(K)	4.5±0.2	4.9±0.1	5.0±0.3	5.4±0.2	6.1±0.3*	6.8±0.2**
钠(Na)	139.1±3.3	135.9±2.5	133.1±2.3	120.0±3.1	107.9±4.2*	98.7±3.5**
氯(Cl)	101.1±1.2	97.9±1.4	95.6±1.2	90.0±1.5	77.2±1.3*	69.7±1.4**
钙(Ca)	2.4±0.1	2.3±0.2	2.0±0.4	1.8±0.2	1.2±0.1*	1.0±0.3**
镁(Mg)	1.0±0.2	0.9±0.1	1.4±0.3	2.0±0.1	2.9±0.2*	3.7±0.1**
磷(P)	1.2±0.1	1.3±0.3	1.8±0.1	2.2±0.1	3.1±0.2*	4.6±0.1**
碳酸氢根	24.2±0.7	22.5±0.4	20.9±0.8	18.8±0.6	14.3±0.8*	10.4±0.5**
阴离子间隙	14.2±0.5	12.4±0.4	11.7±0.5	10.0±0.6	7.0±0.5*	5.8±0.6**
渗透压(mOSM/L)	300.1±4.3	275.9±5.5	253.1±4.3	230.0±5.1	201.9±4.2*	180.7±4.5**

项目	0	20/(mg/kg)	40/(mg/kg)	60/(mg/kg)	80/(mg/kg)	100/(mg/kg)
乳酸脱氢酶(LDH)	145.1±3.2	150.5±4.4	157.6±5.2	169.0±3.5	181.2±3.3*	193.7±4.4*
肌酸激酶(CK)	1240.7±8.6	1257.5±9.2	1267.6±7.8	1298.1±6.6	1371.2±6.4*	1539.7±9.1*
肌酸激酶同工酶(CKMB)	2045.1±7.3	2051.7±6.1	2077.2±8.2	2089.4±7.3	2154.7±8.5*	2218.1±5.8*

项目	0	20/(mg/kg)	40/(mg/kg)	60/(mg/kg)	80/(mg/kg)	100/(mg/kg)
乳酸脱氢酶(LDH)	145.1±3.2	150.5±4.4	157.6±5.2	169.0±3.5	181.2±3.3*	193.7±4.4*
肌酸激酶(CK)	1240.7±8.6	1257.5±9.2	1267.6±7.8	1298.1±6.6	1371.2±6.4*	1539.7±9.1*
肌酸激酶同工酶(CKMB)	2045.1±7.3	2051.7±6.1	2077.2±8.2	2089.4±7.3	2154.7±8.5*	2218.1±5.8*

项目	0	20/(mg/kg)	40/(mg/kg)	60/(mg/kg)	80/(mg/kg)	100/(mg/kg)
总胆固醇(CHOL)	1.2±0.3	1.4±0.1	1.5±0.4	1.7±0.5	3.2±0.6*	3.9±0.4**
甘油三脂(TG)	0.35±0.3	0.34±0.5	0.41±0.2	0.57±0.8	0.81±0.1*	1.2±0.7**
高密度脂蛋白(HDLC)	1.2±0.3	1.4±0.1	1.5±0.4	1.7±0.5	3.2±0.6*	3.9±0.4**
低密度脂蛋白(LDLC)	0.50±0.2	0.49±0.4	0.41±0.3	0.38±0.2	0.29±0.7*	0.20±0.6**
载脂蛋白(A1APOA1)/(g/L)	1.2±0.3	1.4±0.1	1.5±0.4	1.7±0.5	3.2±0.6*	3.9±0.4**
载脂蛋白(BAPOB)/(g/L)	0.95±0.5	0.89±0.7	0.73±0.1	0.67±0.3	0.50±0.4*	0.40±0.5**
载脂蛋白B/A1(B/A1)	0.73	0.74	0.73	0.75	0.74	0.74